Advertisement

Search Results

Advertisement



Your search for Kathleen I. Pritchard, MD, FRCPC,Kathleen I. Pritchard, MD, FRCPC matches 5 pages

Showing 1 - 5


Conquer Cancer Honors Oncology Professionals With Merit Awards at the 2019 ASCO Annual Meeting

Conquer Cancer®, the ASCO Foundation, is pleased to announce the recipients of its 2019 ASCO Annual Meeting Merit Awards. These distinguished awards support oncology trainees who were first authors on abstracts selected for presentation at the ASCO Annual Meeting. This year, Conquer Cancer...

Conquer Cancer Foundation Recognizes 70 Young Oncology Researchers’ Findings With Merit Awards

ASCO’s Conquer Cancer Foundation is pleased to announce the recipients of its Merit Awards in gastrointestinal cancers, clinical immuno-oncology, genitourinary cancers, and cancer survivorship. The following 70 researchers— oncology fellows and trainees honored for the quality and scientific merit...

Revisiting Ovarian Ablation in Early Breast Cancer: A Mismatch Between Global Values and Clinical Practice Guidelines

ASCO recently released a clinical practice guideline update on ovarian suppression as part of the extant guideline on adjuvant endocrine therapy in hormone receptor–positive breast cancer, and the recommendations were summarized in the June 10, 2016, issue of The ASCO Post. Also in this issue,...

breast cancer

Ovarian Suppression in Premenopausal Women With Estrogen Receptor–Positive Breast Cancer

Oophorectomy was the first proposed form of endocrine therapy for women with breast cancer. Over 100 years ago, Thomas Nunn reported a relationship between menopause and regression of breast cancer.1 This incited interest in the induction of menopause as an anticancer therapy, and in 1986, a...

breast cancer

Updated Analysis of Menopausal Hormone Therapy and Breast Cancer Risk

As reviewed in this issue of The ASCO Post, Chlebowski and colleagues1 reported differing patterns of breast cancer risk during or after hormonal therapy with estrogen plus progestin2 or estrogen alone,3 in an analysis of two Women’s Health Initiative (WHI) trials. This recent update on risk...

Advertisement

Advertisement




Advertisement